Pharoah, Paul D P <br/><br/>
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.  [electronic resource] 

 -  Journal of the National Cancer Institute  Aug 2012 
 - 1263-4; author reply 1266-8 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1460-2105 
<br/><br/><label>Standard No.: </label>10.1093/jnci/djs312  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Cytochrome P-450 CYP2D6--genetics<br/>Female<br/>Glucuronosyltransferase--genetics<br/>Humans<br/>Neoplasm Recurrence, Local--epidemiology<br/>Nitriles--therapeutic use<br/>Polymorphism, Single Nucleotide<br/>Postmenopause<br/>Tamoxifen--therapeutic use<br/>Triazoles--therapeutic use